董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vishal Kapoor | 男 | Independent Director | 50 | 9.13万美元 | 未持股 | 2026-06-15 |
| Svetlana Lucas | 女 | Independent Director | 54 | 7.98万美元 | 5.59 | 2026-06-15 |
| Scott Brun | 男 | Independent Director | 58 | 10.21万美元 | 未持股 | 2026-06-15 |
| Judith Shizuru | 女 | Director | 70 | 8.61万美元 | 24.00 | 2026-06-15 |
| Tom Wiggans | 男 | Executive Chairperson of the Board | 74 | 10.98万美元 | 10.96 | 2026-06-15 |
| Jeet Mahal | 男 | Chief Executive Officer,Director and President | 54 | 128.96万美元 | 16.01 | 2026-06-15 |
| Kurt von Emster | 男 | Independent Director | 58 | 10.66万美元 | 2.96 | 2026-06-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tom Wiggans | 男 | Executive Chairperson of the Board | 74 | 10.98万美元 | 10.96 | 2026-06-15 |
| Jeet Mahal | 男 | Chief Executive Officer,Director and President | 54 | 128.96万美元 | 16.01 | 2026-06-15 |
| Herb Cross | 男 | Chief Financial Officer and Corporate Secretary | 54 | 128.35万美元 | 11.69 | 2026-06-15 |
董事简历
中英对照 | 中文 | 英文- Vishal Kapoor
-
Vishal Kapoor，自2020年1月起，我们的总裁于2015年4月至2019年12月在Iveric Bio（原名Ophthotech）工作。作为Iveric Bio公司的首席商务官，他曾负责收购眼科行业领先的基因治疗和治疗资产组合。2014年10月至2015年4月，Kapoor先生担任NPS Pharma的企业发展总监，负责业务发展和投资组合战略，该公司于2015年被Shire收购。从2005年到2014年，Kapoor先生在Genentech任职9年，担任多个职位，包括眼科和CNS管道资产的领先战略，Lucentis营销，业务发展和医疗事务的商业评估。Mr.Kapoor持有Columbia Business School金融和管理工商管理硕士学位和Columbia University生物学学士学位。
Vishal Kapoor has served as a member of Jasper Therapeutics, Inc.'s Board since February 2023. He has been a Partner of Avego Management, LLC, an affiliate of Velan Capital Partners LP, since January 2021, leading their life sciences venture investing strategy. He was previously with Amplitude Healthcare Acquisition Corporation from January 2020 until Jasper Therapeutics, Inc.'s merger with it in September 2021. Prior to that, Mr. Kapoor was Chief Business Officer of Iveric bio, Inc. (formerly known as Ophthotech) from April 2015 to December 2019. At Iveric bio, Inc., he was responsible for acquiring an industry leading portfolio of gene therapy and therapeutic assets in ophthalmology. From October 2014 to April 2015, Mr. Kapoor was Director of Corporate Development at NPS Pharmaceuticals, Inc., which Shire PLC acquired in 2015 for approximately $5.2 billion. From 2005 to 2014, Mr. Kapoor spent nine years at Genentech, Inc. in various positions, including leading strategy for ophthalmology and central nervous system pipeline assets, Lucentis marketing, commercial assessments for business development and medical affairs. In addition, Mr. Kapoor has previously worked at Pfizer Inc. Mr. Kapoor received an MBA in Finance and Management from Columbia Business School in 2004 and a B.A. in Biology from Columbia University in 1997. - Vishal Kapoor，自2020年1月起，我们的总裁于2015年4月至2019年12月在Iveric Bio（原名Ophthotech）工作。作为Iveric Bio公司的首席商务官，他曾负责收购眼科行业领先的基因治疗和治疗资产组合。2014年10月至2015年4月，Kapoor先生担任NPS Pharma的企业发展总监，负责业务发展和投资组合战略，该公司于2015年被Shire收购。从2005年到2014年，Kapoor先生在Genentech任职9年，担任多个职位，包括眼科和CNS管道资产的领先战略，Lucentis营销，业务发展和医疗事务的商业评估。Mr.Kapoor持有Columbia Business School金融和管理工商管理硕士学位和Columbia University生物学学士学位。
- Vishal Kapoor has served as a member of Jasper Therapeutics, Inc.'s Board since February 2023. He has been a Partner of Avego Management, LLC, an affiliate of Velan Capital Partners LP, since January 2021, leading their life sciences venture investing strategy. He was previously with Amplitude Healthcare Acquisition Corporation from January 2020 until Jasper Therapeutics, Inc.'s merger with it in September 2021. Prior to that, Mr. Kapoor was Chief Business Officer of Iveric bio, Inc. (formerly known as Ophthotech) from April 2015 to December 2019. At Iveric bio, Inc., he was responsible for acquiring an industry leading portfolio of gene therapy and therapeutic assets in ophthalmology. From October 2014 to April 2015, Mr. Kapoor was Director of Corporate Development at NPS Pharmaceuticals, Inc., which Shire PLC acquired in 2015 for approximately $5.2 billion. From 2005 to 2014, Mr. Kapoor spent nine years at Genentech, Inc. in various positions, including leading strategy for ophthalmology and central nervous system pipeline assets, Lucentis marketing, commercial assessments for business development and medical affairs. In addition, Mr. Kapoor has previously worked at Pfizer Inc. Mr. Kapoor received an MBA in Finance and Management from Columbia Business School in 2004 and a B.A. in Biology from Columbia University in 1997.
- Svetlana Lucas
-
Svetlana Lucas，自2026年7月起担任Scribe Therapeutics，Inc.首席运营官，此前自2019年6月起担任Scribe Therapeutics，Inc.首席商务官。在加入Scribe Therapeutics，Inc.之前，Lucas博士曾于2015年7月至2019年6月在Tizona Therapeutics，Inc.或Tizona担任多个职责日益增加的职位，包括最近于2019年1月至2019年6月担任业务发展高级副总裁。在加入Tizona之前，Dr. Lucas于2014年8月至2015年7月在安进公司或安进担任肿瘤学和炎症外部研发主管。Lucas博士在安进收购奥尼斯医药（Onyx）后加入安进，她于2012年9月至2014年8月期间担任企业发展总监。在加入Onyx之前，Lucas博士曾在XOMA公司、Facet Biotech（被艾伯维收购）、PDL Biopharma，Inc.和安进担任战略、业务发展和战略营销方面的职责越来越重的职位。卢卡斯博士的职业生涯始于麦肯锡公司生命科学业务的战略顾问。Lucas博士自2024年6月起担任上市生物技术公司Jasper Therapeutics, Inc.的董事会成员，自2019年7月起担任上市生物制药公司aTyr制药，Inc.的董事会成员。自2023年10月以来，卢卡斯博士还担任Radar Therapeutics的顾问。Lucas博士拥有罗蒙诺索夫莫斯科国立大学生物学本科学位，并拥有加州理工学院分子生物学和生物化学博士学位。
Svetlana Lucas,has served as Scribe Therapeutics, Inc. Chief Operating Officer since July 2026 and previously served as Scribe Therapeutics, Inc. Chief Business Officer since June 2019. Prior to joining Scribe Therapeutics, Inc., Dr. Lucas served in various positions of increasing responsibility at Tizona Therapeutics, Inc., or Tizona, from July 2015 to June 2019, including most recently as Senior Vice President, Business Development from January 2019 to June 2019. Before joining Tizona, Dr. Lucas served as Head of Oncology and Inflammation External Research and Development at Amgen Inc., or Amgen, from August 2014 to July 2015. Dr. Lucas joined Amgen following Amgen's acquisition of Onyx Pharmaceuticals, Inc., or Onyx, where she served as the Director of Corporate Development from September 2012 to August 2014. Prior to joining Onyx, Dr. Lucas held positions of increasing responsibility in strategy, business development and strategic marketing at XOMA Corporation, Facet Biotech (acquired by AbbVie), PDL Biopharma, Inc., and Amgen. Dr. Lucas began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Dr. Lucas has served as a member of the boards of directors of Jasper Therapeutics, Inc., a public biotechnology company, since June 2024, and aTyr Pharma, Inc., a public biopharmaceutical company, since July 2019. Dr. Lucas has also served as an advisor to Radar Therapeutics since October 2023. Dr. Lucas holds an undergraduate degree in Biology from Lomonosov Moscow State University and holds a Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology. - Svetlana Lucas，自2026年7月起担任Scribe Therapeutics，Inc.首席运营官，此前自2019年6月起担任Scribe Therapeutics，Inc.首席商务官。在加入Scribe Therapeutics，Inc.之前，Lucas博士曾于2015年7月至2019年6月在Tizona Therapeutics，Inc.或Tizona担任多个职责日益增加的职位，包括最近于2019年1月至2019年6月担任业务发展高级副总裁。在加入Tizona之前，Dr. Lucas于2014年8月至2015年7月在安进公司或安进担任肿瘤学和炎症外部研发主管。Lucas博士在安进收购奥尼斯医药（Onyx）后加入安进，她于2012年9月至2014年8月期间担任企业发展总监。在加入Onyx之前，Lucas博士曾在XOMA公司、Facet Biotech（被艾伯维收购）、PDL Biopharma，Inc.和安进担任战略、业务发展和战略营销方面的职责越来越重的职位。卢卡斯博士的职业生涯始于麦肯锡公司生命科学业务的战略顾问。Lucas博士自2024年6月起担任上市生物技术公司Jasper Therapeutics, Inc.的董事会成员，自2019年7月起担任上市生物制药公司aTyr制药，Inc.的董事会成员。自2023年10月以来，卢卡斯博士还担任Radar Therapeutics的顾问。Lucas博士拥有罗蒙诺索夫莫斯科国立大学生物学本科学位，并拥有加州理工学院分子生物学和生物化学博士学位。
- Svetlana Lucas,has served as Scribe Therapeutics, Inc. Chief Operating Officer since July 2026 and previously served as Scribe Therapeutics, Inc. Chief Business Officer since June 2019. Prior to joining Scribe Therapeutics, Inc., Dr. Lucas served in various positions of increasing responsibility at Tizona Therapeutics, Inc., or Tizona, from July 2015 to June 2019, including most recently as Senior Vice President, Business Development from January 2019 to June 2019. Before joining Tizona, Dr. Lucas served as Head of Oncology and Inflammation External Research and Development at Amgen Inc., or Amgen, from August 2014 to July 2015. Dr. Lucas joined Amgen following Amgen's acquisition of Onyx Pharmaceuticals, Inc., or Onyx, where she served as the Director of Corporate Development from September 2012 to August 2014. Prior to joining Onyx, Dr. Lucas held positions of increasing responsibility in strategy, business development and strategic marketing at XOMA Corporation, Facet Biotech (acquired by AbbVie), PDL Biopharma, Inc., and Amgen. Dr. Lucas began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company. Dr. Lucas has served as a member of the boards of directors of Jasper Therapeutics, Inc., a public biotechnology company, since June 2024, and aTyr Pharma, Inc., a public biopharmaceutical company, since July 2019. Dr. Lucas has also served as an advisor to Radar Therapeutics since October 2023. Dr. Lucas holds an undergraduate degree in Biology from Lomonosov Moscow State University and holds a Ph.D. in Molecular Biology and Biochemistry from the California Institute of Technology.
- Scott Brun
-
Scott Brun，自2023年6月起担任董事会成员。Brun博士目前担任Gold Mast Consulting，LLC的总裁，该公司是他于2019年创立的一家咨询公司，旨在提供与生物制药研发、管道组合管理、新疗法商业化以及与研发活动相关的战略沟通相关的技术建议和战略指导。Brun博士是Abingworth LLP的风险合伙人，也是Launch Therapeutics的高级医疗顾问。在担任现任职务之前，布伦博士在艾伯维公司担任过20年的各种领导职务，其中在前身公司雅培工作了15年。他职业生涯的大部分时间都专注于领导团队和临床开发组织，涉及广泛的治疗领域，包括自身免疫、神经系统和肾脏等。他最近担任科学事务公司副总裁和艾伯维风险投资公司的负责人，艾伯维风险投资公司是一家企业风险基金，负责在2016年3月至2019年3月期间在艾伯维的研发治疗领域以及感兴趣的技术平台内的投资机会。此前，布伦博士曾于2013年11月至2016年3月在艾伯维担任公司副总裁兼药物开发主管。在艾伯维任职期间，布伦博士负责监督一家全球性组织，负责艾伯维早期和后期临床预注册管道化合物的整个产品组合，以及肿瘤学、神经病学、免疫学、肾脏、传染病以及妇女和男子健康治疗领域的已上市化合物。在加入艾伯维之前，Brun博士在雅培工作了超过15年，在那里他在研发组织内的药物开发方面担任领导责任越来越大的职位。Brun博士是Axial Biotherapeutics，Inc.和Trishula Therapeutics，Inc.的董事会成员，这两家公司都是私营的临床阶段生物制药公司，Forte Biosciences, Inc.（纳斯达克：FBRX）是一家专注于自身免疫性疾病的临床前阶段公司，Cabaletta Bio, Inc.TERM3（纳斯达克：CABA）是一家临床阶段生物技术公司，专注于发现和开发针对自身免疫性疾病的工程化T细胞疗法。此前，Brun博士于2020年至2023年在Horizon Therapeutics PLC（纳斯达克：HZNP）担任业务发展团队的高级顾问。布伦博士在伊利诺伊大学厄巴纳-香槟分校获得生物化学学士学位，并在约翰霍普金斯大学医学院获得医学博士学位。他在哈佛医学院麻萨诸塞州眼耳医务室完成了眼科住院医师实习。
Scott Brun has served as a member of Jasper Therapeutics, Inc.'s Board since June 2023. Dr. Brun is currently President at Gold Mast Consulting, LLC, an advisory firm he founded in 2019 to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R&D activities.Prior to joining AbbVie, Dr. Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership responsibility in drug development within the R&D organization. Dr. Brun is a member of the boards of directors of Atsena Therapeutics and Trishula Therapeutics, Inc., both private, clinical stage biopharmaceutical companies, Forte Biosciences, Inc. (Nasdaq: FBRX),a clinical stage company focused on autoimmune diseases, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Previously, Dr. Brun served as a Senior Advisor to the business development team at Horizon Therapeutics plc (Nasdaq: HZNP) from 2020 to 2023. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. - Scott Brun，自2023年6月起担任董事会成员。Brun博士目前担任Gold Mast Consulting，LLC的总裁，该公司是他于2019年创立的一家咨询公司，旨在提供与生物制药研发、管道组合管理、新疗法商业化以及与研发活动相关的战略沟通相关的技术建议和战略指导。Brun博士是Abingworth LLP的风险合伙人，也是Launch Therapeutics的高级医疗顾问。在担任现任职务之前，布伦博士在艾伯维公司担任过20年的各种领导职务，其中在前身公司雅培工作了15年。他职业生涯的大部分时间都专注于领导团队和临床开发组织，涉及广泛的治疗领域，包括自身免疫、神经系统和肾脏等。他最近担任科学事务公司副总裁和艾伯维风险投资公司的负责人，艾伯维风险投资公司是一家企业风险基金，负责在2016年3月至2019年3月期间在艾伯维的研发治疗领域以及感兴趣的技术平台内的投资机会。此前，布伦博士曾于2013年11月至2016年3月在艾伯维担任公司副总裁兼药物开发主管。在艾伯维任职期间，布伦博士负责监督一家全球性组织，负责艾伯维早期和后期临床预注册管道化合物的整个产品组合，以及肿瘤学、神经病学、免疫学、肾脏、传染病以及妇女和男子健康治疗领域的已上市化合物。在加入艾伯维之前，Brun博士在雅培工作了超过15年，在那里他在研发组织内的药物开发方面担任领导责任越来越大的职位。Brun博士是Axial Biotherapeutics，Inc.和Trishula Therapeutics，Inc.的董事会成员，这两家公司都是私营的临床阶段生物制药公司，Forte Biosciences, Inc.（纳斯达克：FBRX）是一家专注于自身免疫性疾病的临床前阶段公司，Cabaletta Bio, Inc.TERM3（纳斯达克：CABA）是一家临床阶段生物技术公司，专注于发现和开发针对自身免疫性疾病的工程化T细胞疗法。此前，Brun博士于2020年至2023年在Horizon Therapeutics PLC（纳斯达克：HZNP）担任业务发展团队的高级顾问。布伦博士在伊利诺伊大学厄巴纳-香槟分校获得生物化学学士学位，并在约翰霍普金斯大学医学院获得医学博士学位。他在哈佛医学院麻萨诸塞州眼耳医务室完成了眼科住院医师实习。
- Scott Brun has served as a member of Jasper Therapeutics, Inc.'s Board since June 2023. Dr. Brun is currently President at Gold Mast Consulting, LLC, an advisory firm he founded in 2019 to provide technical advice and strategic guidance related to biopharmaceutical research and development, pipeline portfolio management, commercialization of new therapeutics and strategic communications related to R&D activities.Prior to joining AbbVie, Dr. Brun spent over 15 years at Abbott Laboratories, where he held positions of increasing leadership responsibility in drug development within the R&D organization. Dr. Brun is a member of the boards of directors of Atsena Therapeutics and Trishula Therapeutics, Inc., both private, clinical stage biopharmaceutical companies, Forte Biosciences, Inc. (Nasdaq: FBRX),a clinical stage company focused on autoimmune diseases, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Previously, Dr. Brun served as a Senior Advisor to the business development team at Horizon Therapeutics plc (Nasdaq: HZNP) from 2020 to 2023. Dr. Brun received his B.S. in Biochemistry from the University of Illinois at Urbana Champaign and earned his M.D. from the Johns Hopkins University School of Medicine. He completed his residency in ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School.
- Judith Shizuru
-
Judith Shizuru，自2021年9月起担任董事会成员。Shizuru博士是Scientific的联合创始人，曾在2018年3月至2021年9月与Amplitude Healthcare Acquisition Corporation（“合并前委员会”）合并之前担任公司董事会成员，并于2019年12月至2021年9月担任其科学顾问委员会主席。Shizuru博士是斯坦福大学的医学（血液和骨髓移植）和儿科（干细胞移植）教授。Shizuru博士是斯坦福大学血液和骨髓移植与细胞疗法（“BMT-CT”）学院、斯坦福大学免疫学项目、斯坦福癌症研究所和干细胞生物学与再生医学研究所的成员。Shizuru博士在本宁顿学院获得学士学位，在斯坦福大学医学院获得医学博士和博士学位。她在加州大学旧金山分校接受成人内科住院医师培训，在斯坦福大学接受血液学子专业培训。Shizuru博士自1997年以来一直参加斯坦福大学BMT-CT临床服务，她负责监督一个研究实验室。她的实验室专注于了解移植的同种异体造血细胞对植入的抗性的细胞和分子基础，以及骨髓移植物改变免疫反应的方式，包括诱导免疫耐受。Shizuru博士的实验室开发了抗CD117抗体的转化科学，并率先将一种抗人CD117抗体作为移植调理剂从实验室推进到临床。Shizuru博士在免疫学和造血细胞移植领域发表了160多篇论文。
Judith Shizuru is Jasper Therapeutics, Inc.'s scientific co founder and served as a member of the board of directors of Jasper Therapeutics, Inc.'s Company prior to the merger with Amplitude Healthcare Acquisition Corporation (the "Pre Merger Board") from March 2018 to September 2021 and as Chair of its Scientific Advisory Board from December 2019 to September 2021. Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. Dr. Shizuru is a member of the Stanford Blood and Marrow Transplantation and Cellular Therapy ("BMT CT") faculty, the Stanford Immunology Program, the Stanford Cancer Institute and the Institute for Stem Cell Biology and Regenerative Medicine. Dr. Shizuru received a Bachelor's degree from Bennington College and an M.D. and Ph.D. from the Stanford University School of Medicine. She trained as a resident in adult internal medicine at the University of California, San Francisco, and in the sub specialty of hematology at Stanford. Dr. Shizuru has been attending on the Stanford BMT CT clinical service since 1997, and she oversees a research laboratory. Her laboratory is focused on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic hematopoietic cells, and the way in which bone marrow grafts modify immune responses including the induction of immune tolerance. Dr. Shizuru's laboratory has developed the translational science of anti CD117 antibodies, and was the first to advance an anti human CD117 antibody as a transplant conditioning agent from the laboratory to the clinic. Dr. Shizuru has over 175 publications in the fields of immunology and hematopoietic cell transplantation. - Judith Shizuru，自2021年9月起担任董事会成员。Shizuru博士是Scientific的联合创始人，曾在2018年3月至2021年9月与Amplitude Healthcare Acquisition Corporation（“合并前委员会”）合并之前担任公司董事会成员，并于2019年12月至2021年9月担任其科学顾问委员会主席。Shizuru博士是斯坦福大学的医学（血液和骨髓移植）和儿科（干细胞移植）教授。Shizuru博士是斯坦福大学血液和骨髓移植与细胞疗法（“BMT-CT”）学院、斯坦福大学免疫学项目、斯坦福癌症研究所和干细胞生物学与再生医学研究所的成员。Shizuru博士在本宁顿学院获得学士学位，在斯坦福大学医学院获得医学博士和博士学位。她在加州大学旧金山分校接受成人内科住院医师培训，在斯坦福大学接受血液学子专业培训。Shizuru博士自1997年以来一直参加斯坦福大学BMT-CT临床服务，她负责监督一个研究实验室。她的实验室专注于了解移植的同种异体造血细胞对植入的抗性的细胞和分子基础，以及骨髓移植物改变免疫反应的方式，包括诱导免疫耐受。Shizuru博士的实验室开发了抗CD117抗体的转化科学，并率先将一种抗人CD117抗体作为移植调理剂从实验室推进到临床。Shizuru博士在免疫学和造血细胞移植领域发表了160多篇论文。
- Judith Shizuru is Jasper Therapeutics, Inc.'s scientific co founder and served as a member of the board of directors of Jasper Therapeutics, Inc.'s Company prior to the merger with Amplitude Healthcare Acquisition Corporation (the "Pre Merger Board") from March 2018 to September 2021 and as Chair of its Scientific Advisory Board from December 2019 to September 2021. Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at Stanford. Dr. Shizuru is a member of the Stanford Blood and Marrow Transplantation and Cellular Therapy ("BMT CT") faculty, the Stanford Immunology Program, the Stanford Cancer Institute and the Institute for Stem Cell Biology and Regenerative Medicine. Dr. Shizuru received a Bachelor's degree from Bennington College and an M.D. and Ph.D. from the Stanford University School of Medicine. She trained as a resident in adult internal medicine at the University of California, San Francisco, and in the sub specialty of hematology at Stanford. Dr. Shizuru has been attending on the Stanford BMT CT clinical service since 1997, and she oversees a research laboratory. Her laboratory is focused on understanding the cellular and molecular basis of resistance to engraftment of transplanted allogeneic hematopoietic cells, and the way in which bone marrow grafts modify immune responses including the induction of immune tolerance. Dr. Shizuru's laboratory has developed the translational science of anti CD117 antibodies, and was the first to advance an anti human CD117 antibody as a transplant conditioning agent from the laboratory to the clinic. Dr. Shizuru has over 175 publications in the fields of immunology and hematopoietic cell transplantation.
- Tom Wiggans
-
Tom Wiggans，自2023年11月起担任董事会成员和主席。他最近于2022年3月担任Pardes Biosciences, Inc.（纳斯达克：PRDS）的首席执行官兼董事会主席，直至2023年8月与MediPacific，Inc.合并。Wiggans先生于2010年8月创立了Dermira, Inc.（纳斯达克：DERM），并于2010年8月起担任其首席执行官和董事会成员，并于2014年4月起担任其董事会主席，直至Dermira于2020年被礼来 and Company收购。从2007年10月起，Wiggans先生担任Peplin，Inc.的董事会主席，并于2008年8月成为其首席执行官，担任这些职务，直到Peplin于2009年11月被LEO Pharma Inc.收购。此前，Wiggans先生从1994年起担任Connetics USA的首席执行官，并从2006年1月起担任Connetics的董事会主席，直到2006年12月Connetics被Stiefel Laboratories，Inc.收购。从1992年到1994年，Wiggans先生担任生物技术公司CytoTherapeutics，Inc.的总裁兼首席运营官。从1980年到1992年，Wiggans先生曾在Ares-Serono S.A.担任多个管理职务，包括担任其美国制药业务总裁和英国制药业务董事总经理。威甘斯先生的职业生涯始于礼来公司。他目前在Annexon, Inc.（纳斯达克：ANNX）的董事会任职，自2017年2月起担任该职务。Wiggans先生此前曾在多家行业组织、教育机构以及私营和上市公司的董事会任职，包括自2021年4月起至2024年3月被吉利德科学，Inc.收购之前在Cymabay Therapeutics, Inc.（纳斯达克：CBAY）的董事会任职，自2005年3月起至2013年10月被安进，Inc.收购之前在Onyx Pharmaceuticals Inc.任职，自2008年6月至2012年6月担任Sangamo Biosciences，Inc.，自2008年6月至2012年6月担任Somaxon Pharmaceuticals，Inc.自2008年6月至2012年5月担任职务，自2020年9月起至2022年10月被Novo Nordisk A/S收购之前在Forma Therapeutics Holdings，并于2010年10月起担任Excaliard Pharmaceuticals，Inc.董事会主席，直至其于2011年12月被辉瑞收购。Wiggans先生在生物技术行业组织的组建过程中发挥了重要作用，并担任了多年的董事会成员。他目前是堪萨斯大学捐赠协会董事会成员。Wiggans先生拥有堪萨斯大学的药学学士学位和南方卫理公会大学的工商管理硕士学位。
Tom Wiggans has served as a member of Jasper Therapeutics, Inc.'s Board since November 2023. He was appointed as Executive Chairperson of the Board in January 2026 and served as Chairperson of the Board from November 2023 until his appointment as Executive Chairperson. He most recently served as the Chief Executive Officer and chair of the board of directors of Pardes Biosciences, Inc. (Nasdaq: PRDS) from March 2022 until its merger with MediPacific, Inc. in August 2023. Mr. Wiggans founded Dermira, Inc. (Nasdaq: DERM) in August 2010, and served as its Chief Executive Officer and a member of its board of directors from August 2010 and as the chairman of its board of directors from April 2014 until Dermira's acquisition by Eli Lilly and Company in 2020. From October 2007, Mr. Wiggans served as chairman of the board of directors of Peplin, Inc. and in August 2008, he became its Chief Executive Officer, serving in these positions until Peplin's acquisition by LEO Pharma Inc. in November 2009. Previously, Mr. Wiggans served as chief executive officer of Connetics USA from 1994, and as chairman of the board of directors of Connetics from January 2006 until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, Inc., a biotechnology company. From 1980 to 1992, Mr. Wiggans served at Ares Serono S.A. in various management positions, including as President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly and Company. He currently serves on the board of directors of Annexon, Inc. (Nasdaq: ANNX), a position he has held since February 2017. Mr. Wiggans has previously served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Cymabay Therapeutics, Inc. (Nasdaq: CBAY) from April 2021 until its acquisition by Gilead Sciences, Inc. in March 2024, Onyx Pharmaceuticals Inc. from March 2005 until its acquisition by Amgen Inc. in October 2013, Sangamo Biosciences, Inc. from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012, Forma Therapeutics Holdings, Inc. from September 2020 until its acquisition by Novo Nordisk A/S in October 2022, and as chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer Inc. in December 2011. Mr. Wiggans was instrumental in the formation of the Biotechnology Industry Organization and served as a member of its board of directors for many years. He is currently a member of the Board of Trustees of the University of Kansas Endowment Association. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University. - Tom Wiggans，自2023年11月起担任董事会成员和主席。他最近于2022年3月担任Pardes Biosciences, Inc.（纳斯达克：PRDS）的首席执行官兼董事会主席，直至2023年8月与MediPacific，Inc.合并。Wiggans先生于2010年8月创立了Dermira, Inc.（纳斯达克：DERM），并于2010年8月起担任其首席执行官和董事会成员，并于2014年4月起担任其董事会主席，直至Dermira于2020年被礼来 and Company收购。从2007年10月起，Wiggans先生担任Peplin，Inc.的董事会主席，并于2008年8月成为其首席执行官，担任这些职务，直到Peplin于2009年11月被LEO Pharma Inc.收购。此前，Wiggans先生从1994年起担任Connetics USA的首席执行官，并从2006年1月起担任Connetics的董事会主席，直到2006年12月Connetics被Stiefel Laboratories，Inc.收购。从1992年到1994年，Wiggans先生担任生物技术公司CytoTherapeutics，Inc.的总裁兼首席运营官。从1980年到1992年，Wiggans先生曾在Ares-Serono S.A.担任多个管理职务，包括担任其美国制药业务总裁和英国制药业务董事总经理。威甘斯先生的职业生涯始于礼来公司。他目前在Annexon, Inc.（纳斯达克：ANNX）的董事会任职，自2017年2月起担任该职务。Wiggans先生此前曾在多家行业组织、教育机构以及私营和上市公司的董事会任职，包括自2021年4月起至2024年3月被吉利德科学，Inc.收购之前在Cymabay Therapeutics, Inc.（纳斯达克：CBAY）的董事会任职，自2005年3月起至2013年10月被安进，Inc.收购之前在Onyx Pharmaceuticals Inc.任职，自2008年6月至2012年6月担任Sangamo Biosciences，Inc.，自2008年6月至2012年6月担任Somaxon Pharmaceuticals，Inc.自2008年6月至2012年5月担任职务，自2020年9月起至2022年10月被Novo Nordisk A/S收购之前在Forma Therapeutics Holdings，并于2010年10月起担任Excaliard Pharmaceuticals，Inc.董事会主席，直至其于2011年12月被辉瑞收购。Wiggans先生在生物技术行业组织的组建过程中发挥了重要作用，并担任了多年的董事会成员。他目前是堪萨斯大学捐赠协会董事会成员。Wiggans先生拥有堪萨斯大学的药学学士学位和南方卫理公会大学的工商管理硕士学位。
- Tom Wiggans has served as a member of Jasper Therapeutics, Inc.'s Board since November 2023. He was appointed as Executive Chairperson of the Board in January 2026 and served as Chairperson of the Board from November 2023 until his appointment as Executive Chairperson. He most recently served as the Chief Executive Officer and chair of the board of directors of Pardes Biosciences, Inc. (Nasdaq: PRDS) from March 2022 until its merger with MediPacific, Inc. in August 2023. Mr. Wiggans founded Dermira, Inc. (Nasdaq: DERM) in August 2010, and served as its Chief Executive Officer and a member of its board of directors from August 2010 and as the chairman of its board of directors from April 2014 until Dermira's acquisition by Eli Lilly and Company in 2020. From October 2007, Mr. Wiggans served as chairman of the board of directors of Peplin, Inc. and in August 2008, he became its Chief Executive Officer, serving in these positions until Peplin's acquisition by LEO Pharma Inc. in November 2009. Previously, Mr. Wiggans served as chief executive officer of Connetics USA from 1994, and as chairman of the board of directors of Connetics from January 2006 until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, Inc., a biotechnology company. From 1980 to 1992, Mr. Wiggans served at Ares Serono S.A. in various management positions, including as President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly and Company. He currently serves on the board of directors of Annexon, Inc. (Nasdaq: ANNX), a position he has held since February 2017. Mr. Wiggans has previously served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Cymabay Therapeutics, Inc. (Nasdaq: CBAY) from April 2021 until its acquisition by Gilead Sciences, Inc. in March 2024, Onyx Pharmaceuticals Inc. from March 2005 until its acquisition by Amgen Inc. in October 2013, Sangamo Biosciences, Inc. from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012, Forma Therapeutics Holdings, Inc. from September 2020 until its acquisition by Novo Nordisk A/S in October 2022, and as chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer Inc. in December 2011. Mr. Wiggans was instrumental in the formation of the Biotechnology Industry Organization and served as a member of its board of directors for many years. He is currently a member of the Board of Trustees of the University of Kansas Endowment Association. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
- Jeet Mahal
-
Jeet Mahal自2026年1月起担任Jasper Therapeutics, Inc.的总裁、首席执行官以及Jasper Therapeutics, Inc.董事会成员。在此之前，Mahal先生自2022年3月起担任Jasper Therapeutics, Inc.的首席运营官。他于2021年9月至2023年9月担任Jasper Therapeutics, Inc.的首席财务官和公司秘书，并于2021年9月至2022年3月担任Jasper Therapeutics, Inc.的首席商务官。在此之前，Mahal先生自2019年12月起担任Jasper Therapeutics, Inc.的首席财务和商务官。在加入Jasper Therapeutics, Inc.的公司之前，Mahal先生于2008年8月至2019年12月在波尔图制药公司工作，Mahal先生曾担任多个领导职务，最近一次是在2019年1月至2019年12月担任战略营销副总裁，在2013年2月至2018年12月担任业务发展副总裁。在Portola Pharmaceuticals, Inc.期间，Mahal先生领导了Andexxa多个业务发展合作伙伴关系的执行工作，bevyxxa和cerdulatinib。马哈尔还在该公司的股权融资中发挥了关键作用，包括首次公开募股和多项特许权使用费交易。在其职业生涯的早期，从2006年1月到2008年9月，Mahal先生在强生担任业务和新产品开发总监，负责心血管领域的许可和拜瑞妥产品开发团队。Mahal先生的职业生涯始于COR Therapeutics的药物开发实验室。Mahal先生拥有U.C. Berkeley的分子和细胞生物学学士学位、北卡罗来纳州立大学的工程学硕士学位、伊利诺伊理工学院的分子和细胞生物学硕士学位以及杜克大学的MBA学位。
Jeet Mahal has served as Jasper Therapeutics, Inc.'s President, Chief Executive Officer and a member of Jasper Therapeutics, Inc.'s Board since January 2026. Prior to that, Mr. Mahal served as Jasper Therapeutics, Inc.'s Chief Operating Officer from March 2022. He served as Jasper Therapeutics, Inc.'s Chief Financial Officer and Corporate Secretary from September 2021 to September 2023 and as Jasper Therapeutics, Inc.'s Chief Business Officer from September 2021 to March 2022. Prior to that, Mr. Mahal had served as Jasper Therapeutics, Inc.'s Chief Financial and Business Officer since December 2019. Prior to joining Jasper Therapeutics, Inc.'s Company, Mr. Mahal worked at Portola Pharmaceuticals, Inc. from August 2008 to December 2019, where Mr. Mahal held a number of positions of increasing leadership, most recently as Vice President, Strategic Marketing from January 2019 to December 2019 and Vice President, Business Development from February 2013 to December 2018. While at Portola Pharmaceuticals, Inc., Mr. Mahal led the execution of multiple business development partnerships for Andexxa, Bevyxxa and cerdulatinib. Mr. Mahal also played a key role in the company's equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, from January 2006 to September 2008, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the cardiovascular in licensing and Xarelto product development teams. Mr. Mahal started his career in the drug development laboratories at COR Therapeutics. Mr. Mahal holds a Bachelor's degree in Molecular and Cell Biology from U.C. Berkeley, a Master's degree in Engineering from North Carolina State University, a Master's degree in Molecular and Cell Biology from the Illinois Institute of Technology and an MBA from Duke University. - Jeet Mahal自2026年1月起担任Jasper Therapeutics, Inc.的总裁、首席执行官以及Jasper Therapeutics, Inc.董事会成员。在此之前，Mahal先生自2022年3月起担任Jasper Therapeutics, Inc.的首席运营官。他于2021年9月至2023年9月担任Jasper Therapeutics, Inc.的首席财务官和公司秘书，并于2021年9月至2022年3月担任Jasper Therapeutics, Inc.的首席商务官。在此之前，Mahal先生自2019年12月起担任Jasper Therapeutics, Inc.的首席财务和商务官。在加入Jasper Therapeutics, Inc.的公司之前，Mahal先生于2008年8月至2019年12月在波尔图制药公司工作，Mahal先生曾担任多个领导职务，最近一次是在2019年1月至2019年12月担任战略营销副总裁，在2013年2月至2018年12月担任业务发展副总裁。在Portola Pharmaceuticals, Inc.期间，Mahal先生领导了Andexxa多个业务发展合作伙伴关系的执行工作，bevyxxa和cerdulatinib。马哈尔还在该公司的股权融资中发挥了关键作用，包括首次公开募股和多项特许权使用费交易。在其职业生涯的早期，从2006年1月到2008年9月，Mahal先生在强生担任业务和新产品开发总监，负责心血管领域的许可和拜瑞妥产品开发团队。Mahal先生的职业生涯始于COR Therapeutics的药物开发实验室。Mahal先生拥有U.C. Berkeley的分子和细胞生物学学士学位、北卡罗来纳州立大学的工程学硕士学位、伊利诺伊理工学院的分子和细胞生物学硕士学位以及杜克大学的MBA学位。
- Jeet Mahal has served as Jasper Therapeutics, Inc.'s President, Chief Executive Officer and a member of Jasper Therapeutics, Inc.'s Board since January 2026. Prior to that, Mr. Mahal served as Jasper Therapeutics, Inc.'s Chief Operating Officer from March 2022. He served as Jasper Therapeutics, Inc.'s Chief Financial Officer and Corporate Secretary from September 2021 to September 2023 and as Jasper Therapeutics, Inc.'s Chief Business Officer from September 2021 to March 2022. Prior to that, Mr. Mahal had served as Jasper Therapeutics, Inc.'s Chief Financial and Business Officer since December 2019. Prior to joining Jasper Therapeutics, Inc.'s Company, Mr. Mahal worked at Portola Pharmaceuticals, Inc. from August 2008 to December 2019, where Mr. Mahal held a number of positions of increasing leadership, most recently as Vice President, Strategic Marketing from January 2019 to December 2019 and Vice President, Business Development from February 2013 to December 2018. While at Portola Pharmaceuticals, Inc., Mr. Mahal led the execution of multiple business development partnerships for Andexxa, Bevyxxa and cerdulatinib. Mr. Mahal also played a key role in the company's equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, from January 2006 to September 2008, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the cardiovascular in licensing and Xarelto product development teams. Mr. Mahal started his career in the drug development laboratories at COR Therapeutics. Mr. Mahal holds a Bachelor's degree in Molecular and Cell Biology from U.C. Berkeley, a Master's degree in Engineering from North Carolina State University, a Master's degree in Molecular and Cell Biology from the Illinois Institute of Technology and an MBA from Duke University.
- Kurt von Emster
-
Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA). - Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
- Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA).
高管简历
中英对照 | 中文 | 英文- Tom Wiggans
Tom Wiggans，自2023年11月起担任董事会成员和主席。他最近于2022年3月担任Pardes Biosciences, Inc.（纳斯达克：PRDS）的首席执行官兼董事会主席，直至2023年8月与MediPacific，Inc.合并。Wiggans先生于2010年8月创立了Dermira, Inc.（纳斯达克：DERM），并于2010年8月起担任其首席执行官和董事会成员，并于2014年4月起担任其董事会主席，直至Dermira于2020年被礼来 and Company收购。从2007年10月起，Wiggans先生担任Peplin，Inc.的董事会主席，并于2008年8月成为其首席执行官，担任这些职务，直到Peplin于2009年11月被LEO Pharma Inc.收购。此前，Wiggans先生从1994年起担任Connetics USA的首席执行官，并从2006年1月起担任Connetics的董事会主席，直到2006年12月Connetics被Stiefel Laboratories，Inc.收购。从1992年到1994年，Wiggans先生担任生物技术公司CytoTherapeutics，Inc.的总裁兼首席运营官。从1980年到1992年，Wiggans先生曾在Ares-Serono S.A.担任多个管理职务，包括担任其美国制药业务总裁和英国制药业务董事总经理。威甘斯先生的职业生涯始于礼来公司。他目前在Annexon, Inc.（纳斯达克：ANNX）的董事会任职，自2017年2月起担任该职务。Wiggans先生此前曾在多家行业组织、教育机构以及私营和上市公司的董事会任职，包括自2021年4月起至2024年3月被吉利德科学，Inc.收购之前在Cymabay Therapeutics, Inc.（纳斯达克：CBAY）的董事会任职，自2005年3月起至2013年10月被安进，Inc.收购之前在Onyx Pharmaceuticals Inc.任职，自2008年6月至2012年6月担任Sangamo Biosciences，Inc.，自2008年6月至2012年6月担任Somaxon Pharmaceuticals，Inc.自2008年6月至2012年5月担任职务，自2020年9月起至2022年10月被Novo Nordisk A/S收购之前在Forma Therapeutics Holdings，并于2010年10月起担任Excaliard Pharmaceuticals，Inc.董事会主席，直至其于2011年12月被辉瑞收购。Wiggans先生在生物技术行业组织的组建过程中发挥了重要作用，并担任了多年的董事会成员。他目前是堪萨斯大学捐赠协会董事会成员。Wiggans先生拥有堪萨斯大学的药学学士学位和南方卫理公会大学的工商管理硕士学位。
Tom Wiggans has served as a member of Jasper Therapeutics, Inc.'s Board since November 2023. He was appointed as Executive Chairperson of the Board in January 2026 and served as Chairperson of the Board from November 2023 until his appointment as Executive Chairperson. He most recently served as the Chief Executive Officer and chair of the board of directors of Pardes Biosciences, Inc. (Nasdaq: PRDS) from March 2022 until its merger with MediPacific, Inc. in August 2023. Mr. Wiggans founded Dermira, Inc. (Nasdaq: DERM) in August 2010, and served as its Chief Executive Officer and a member of its board of directors from August 2010 and as the chairman of its board of directors from April 2014 until Dermira's acquisition by Eli Lilly and Company in 2020. From October 2007, Mr. Wiggans served as chairman of the board of directors of Peplin, Inc. and in August 2008, he became its Chief Executive Officer, serving in these positions until Peplin's acquisition by LEO Pharma Inc. in November 2009. Previously, Mr. Wiggans served as chief executive officer of Connetics USA from 1994, and as chairman of the board of directors of Connetics from January 2006 until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, Inc., a biotechnology company. From 1980 to 1992, Mr. Wiggans served at Ares Serono S.A. in various management positions, including as President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly and Company. He currently serves on the board of directors of Annexon, Inc. (Nasdaq: ANNX), a position he has held since February 2017. Mr. Wiggans has previously served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Cymabay Therapeutics, Inc. (Nasdaq: CBAY) from April 2021 until its acquisition by Gilead Sciences, Inc. in March 2024, Onyx Pharmaceuticals Inc. from March 2005 until its acquisition by Amgen Inc. in October 2013, Sangamo Biosciences, Inc. from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012, Forma Therapeutics Holdings, Inc. from September 2020 until its acquisition by Novo Nordisk A/S in October 2022, and as chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer Inc. in December 2011. Mr. Wiggans was instrumental in the formation of the Biotechnology Industry Organization and served as a member of its board of directors for many years. He is currently a member of the Board of Trustees of the University of Kansas Endowment Association. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.- Tom Wiggans，自2023年11月起担任董事会成员和主席。他最近于2022年3月担任Pardes Biosciences, Inc.（纳斯达克：PRDS）的首席执行官兼董事会主席，直至2023年8月与MediPacific，Inc.合并。Wiggans先生于2010年8月创立了Dermira, Inc.（纳斯达克：DERM），并于2010年8月起担任其首席执行官和董事会成员，并于2014年4月起担任其董事会主席，直至Dermira于2020年被礼来 and Company收购。从2007年10月起，Wiggans先生担任Peplin，Inc.的董事会主席，并于2008年8月成为其首席执行官，担任这些职务，直到Peplin于2009年11月被LEO Pharma Inc.收购。此前，Wiggans先生从1994年起担任Connetics USA的首席执行官，并从2006年1月起担任Connetics的董事会主席，直到2006年12月Connetics被Stiefel Laboratories，Inc.收购。从1992年到1994年，Wiggans先生担任生物技术公司CytoTherapeutics，Inc.的总裁兼首席运营官。从1980年到1992年，Wiggans先生曾在Ares-Serono S.A.担任多个管理职务，包括担任其美国制药业务总裁和英国制药业务董事总经理。威甘斯先生的职业生涯始于礼来公司。他目前在Annexon, Inc.（纳斯达克：ANNX）的董事会任职，自2017年2月起担任该职务。Wiggans先生此前曾在多家行业组织、教育机构以及私营和上市公司的董事会任职，包括自2021年4月起至2024年3月被吉利德科学，Inc.收购之前在Cymabay Therapeutics, Inc.（纳斯达克：CBAY）的董事会任职，自2005年3月起至2013年10月被安进，Inc.收购之前在Onyx Pharmaceuticals Inc.任职，自2008年6月至2012年6月担任Sangamo Biosciences，Inc.，自2008年6月至2012年6月担任Somaxon Pharmaceuticals，Inc.自2008年6月至2012年5月担任职务，自2020年9月起至2022年10月被Novo Nordisk A/S收购之前在Forma Therapeutics Holdings，并于2010年10月起担任Excaliard Pharmaceuticals，Inc.董事会主席，直至其于2011年12月被辉瑞收购。Wiggans先生在生物技术行业组织的组建过程中发挥了重要作用，并担任了多年的董事会成员。他目前是堪萨斯大学捐赠协会董事会成员。Wiggans先生拥有堪萨斯大学的药学学士学位和南方卫理公会大学的工商管理硕士学位。
- Tom Wiggans has served as a member of Jasper Therapeutics, Inc.'s Board since November 2023. He was appointed as Executive Chairperson of the Board in January 2026 and served as Chairperson of the Board from November 2023 until his appointment as Executive Chairperson. He most recently served as the Chief Executive Officer and chair of the board of directors of Pardes Biosciences, Inc. (Nasdaq: PRDS) from March 2022 until its merger with MediPacific, Inc. in August 2023. Mr. Wiggans founded Dermira, Inc. (Nasdaq: DERM) in August 2010, and served as its Chief Executive Officer and a member of its board of directors from August 2010 and as the chairman of its board of directors from April 2014 until Dermira's acquisition by Eli Lilly and Company in 2020. From October 2007, Mr. Wiggans served as chairman of the board of directors of Peplin, Inc. and in August 2008, he became its Chief Executive Officer, serving in these positions until Peplin's acquisition by LEO Pharma Inc. in November 2009. Previously, Mr. Wiggans served as chief executive officer of Connetics USA from 1994, and as chairman of the board of directors of Connetics from January 2006 until December 2006 when Connetics was acquired by Stiefel Laboratories, Inc. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics, Inc., a biotechnology company. From 1980 to 1992, Mr. Wiggans served at Ares Serono S.A. in various management positions, including as President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly and Company. He currently serves on the board of directors of Annexon, Inc. (Nasdaq: ANNX), a position he has held since February 2017. Mr. Wiggans has previously served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Cymabay Therapeutics, Inc. (Nasdaq: CBAY) from April 2021 until its acquisition by Gilead Sciences, Inc. in March 2024, Onyx Pharmaceuticals Inc. from March 2005 until its acquisition by Amgen Inc. in October 2013, Sangamo Biosciences, Inc. from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012, Forma Therapeutics Holdings, Inc. from September 2020 until its acquisition by Novo Nordisk A/S in October 2022, and as chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer Inc. in December 2011. Mr. Wiggans was instrumental in the formation of the Biotechnology Industry Organization and served as a member of its board of directors for many years. He is currently a member of the Board of Trustees of the University of Kansas Endowment Association. Mr. Wiggans holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
- Jeet Mahal
Jeet Mahal自2026年1月起担任Jasper Therapeutics, Inc.的总裁、首席执行官以及Jasper Therapeutics, Inc.董事会成员。在此之前，Mahal先生自2022年3月起担任Jasper Therapeutics, Inc.的首席运营官。他于2021年9月至2023年9月担任Jasper Therapeutics, Inc.的首席财务官和公司秘书，并于2021年9月至2022年3月担任Jasper Therapeutics, Inc.的首席商务官。在此之前，Mahal先生自2019年12月起担任Jasper Therapeutics, Inc.的首席财务和商务官。在加入Jasper Therapeutics, Inc.的公司之前，Mahal先生于2008年8月至2019年12月在波尔图制药公司工作，Mahal先生曾担任多个领导职务，最近一次是在2019年1月至2019年12月担任战略营销副总裁，在2013年2月至2018年12月担任业务发展副总裁。在Portola Pharmaceuticals, Inc.期间，Mahal先生领导了Andexxa多个业务发展合作伙伴关系的执行工作，bevyxxa和cerdulatinib。马哈尔还在该公司的股权融资中发挥了关键作用，包括首次公开募股和多项特许权使用费交易。在其职业生涯的早期，从2006年1月到2008年9月，Mahal先生在强生担任业务和新产品开发总监，负责心血管领域的许可和拜瑞妥产品开发团队。Mahal先生的职业生涯始于COR Therapeutics的药物开发实验室。Mahal先生拥有U.C. Berkeley的分子和细胞生物学学士学位、北卡罗来纳州立大学的工程学硕士学位、伊利诺伊理工学院的分子和细胞生物学硕士学位以及杜克大学的MBA学位。
Jeet Mahal has served as Jasper Therapeutics, Inc.'s President, Chief Executive Officer and a member of Jasper Therapeutics, Inc.'s Board since January 2026. Prior to that, Mr. Mahal served as Jasper Therapeutics, Inc.'s Chief Operating Officer from March 2022. He served as Jasper Therapeutics, Inc.'s Chief Financial Officer and Corporate Secretary from September 2021 to September 2023 and as Jasper Therapeutics, Inc.'s Chief Business Officer from September 2021 to March 2022. Prior to that, Mr. Mahal had served as Jasper Therapeutics, Inc.'s Chief Financial and Business Officer since December 2019. Prior to joining Jasper Therapeutics, Inc.'s Company, Mr. Mahal worked at Portola Pharmaceuticals, Inc. from August 2008 to December 2019, where Mr. Mahal held a number of positions of increasing leadership, most recently as Vice President, Strategic Marketing from January 2019 to December 2019 and Vice President, Business Development from February 2013 to December 2018. While at Portola Pharmaceuticals, Inc., Mr. Mahal led the execution of multiple business development partnerships for Andexxa, Bevyxxa and cerdulatinib. Mr. Mahal also played a key role in the company's equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, from January 2006 to September 2008, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the cardiovascular in licensing and Xarelto product development teams. Mr. Mahal started his career in the drug development laboratories at COR Therapeutics. Mr. Mahal holds a Bachelor's degree in Molecular and Cell Biology from U.C. Berkeley, a Master's degree in Engineering from North Carolina State University, a Master's degree in Molecular and Cell Biology from the Illinois Institute of Technology and an MBA from Duke University.- Jeet Mahal自2026年1月起担任Jasper Therapeutics, Inc.的总裁、首席执行官以及Jasper Therapeutics, Inc.董事会成员。在此之前，Mahal先生自2022年3月起担任Jasper Therapeutics, Inc.的首席运营官。他于2021年9月至2023年9月担任Jasper Therapeutics, Inc.的首席财务官和公司秘书，并于2021年9月至2022年3月担任Jasper Therapeutics, Inc.的首席商务官。在此之前，Mahal先生自2019年12月起担任Jasper Therapeutics, Inc.的首席财务和商务官。在加入Jasper Therapeutics, Inc.的公司之前，Mahal先生于2008年8月至2019年12月在波尔图制药公司工作，Mahal先生曾担任多个领导职务，最近一次是在2019年1月至2019年12月担任战略营销副总裁，在2013年2月至2018年12月担任业务发展副总裁。在Portola Pharmaceuticals, Inc.期间，Mahal先生领导了Andexxa多个业务发展合作伙伴关系的执行工作，bevyxxa和cerdulatinib。马哈尔还在该公司的股权融资中发挥了关键作用，包括首次公开募股和多项特许权使用费交易。在其职业生涯的早期，从2006年1月到2008年9月，Mahal先生在强生担任业务和新产品开发总监，负责心血管领域的许可和拜瑞妥产品开发团队。Mahal先生的职业生涯始于COR Therapeutics的药物开发实验室。Mahal先生拥有U.C. Berkeley的分子和细胞生物学学士学位、北卡罗来纳州立大学的工程学硕士学位、伊利诺伊理工学院的分子和细胞生物学硕士学位以及杜克大学的MBA学位。
- Jeet Mahal has served as Jasper Therapeutics, Inc.'s President, Chief Executive Officer and a member of Jasper Therapeutics, Inc.'s Board since January 2026. Prior to that, Mr. Mahal served as Jasper Therapeutics, Inc.'s Chief Operating Officer from March 2022. He served as Jasper Therapeutics, Inc.'s Chief Financial Officer and Corporate Secretary from September 2021 to September 2023 and as Jasper Therapeutics, Inc.'s Chief Business Officer from September 2021 to March 2022. Prior to that, Mr. Mahal had served as Jasper Therapeutics, Inc.'s Chief Financial and Business Officer since December 2019. Prior to joining Jasper Therapeutics, Inc.'s Company, Mr. Mahal worked at Portola Pharmaceuticals, Inc. from August 2008 to December 2019, where Mr. Mahal held a number of positions of increasing leadership, most recently as Vice President, Strategic Marketing from January 2019 to December 2019 and Vice President, Business Development from February 2013 to December 2018. While at Portola Pharmaceuticals, Inc., Mr. Mahal led the execution of multiple business development partnerships for Andexxa, Bevyxxa and cerdulatinib. Mr. Mahal also played a key role in the company's equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, from January 2006 to September 2008, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the cardiovascular in licensing and Xarelto product development teams. Mr. Mahal started his career in the drug development laboratories at COR Therapeutics. Mr. Mahal holds a Bachelor's degree in Molecular and Cell Biology from U.C. Berkeley, a Master's degree in Engineering from North Carolina State University, a Master's degree in Molecular and Cell Biology from the Illinois Institute of Technology and an MBA from Duke University.
- Herb Cross
Herb Cross，自2023年9月起担任首席财务官、公司秘书。此前，Cross先生自2019年2月起担任生物技术公司Atreca, Inc.的首席财务官。2017年11月至2018年6月，担任生物技术公司ARMO Biosciences，Inc.的首席财务官。2016年2月至2017年11月，Cross先生在生物技术公司Balance Therapeutics，Inc.担任首席财务官。2013年10月至2015年11月，担任生物技术公司KaloBios制药，Inc.的首席财务官，并于2015年1月至2015年11月担任临时首席执行官。2015年12月，KaloBios根据《破产法》第11章提交了一份自愿救济申请。KaloBios于2016年7月从第11章出现。2010年11月至2013年6月，Cross先生在生物技术公司Affymax, Inc.担任首席财务官。2022年7月至2023年8月担任Apexigen，Inc.董事，2019年10月至2023年8月担任Apexigen美国公司董事。Cross先生在加州大学伯克利分校获得工商管理学士学位，是一名注册会计师（非在职）。
Herb Cross had served as the Chief Financial Officer of Atreca, Inc., a biotechnology company, since February 2019. From November 2017 to June 2018, he served as Chief Financial Officer of ARMO Biosciences, Inc., a biotechnology company. From February 2016 to November 2017, Mr. Cross served as Chief Financial Officer of Balance Therapeutics, Inc., a biotechnology company. From October 2013 to November 2015, he served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc., a biotechnology company, and interim Chief Executive Officer from January 2015 to November 2015. From November 2010 to June 2013, Mr. Cross served as Chief Financial Officer of Affymax, Inc., a biotechnology company. He served as a director of Apexigen, Inc. from July 2022 to August 2023 and Apexigen America, Inc. from October 2019 to August 2023. Mr. Cross received a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive).- Herb Cross，自2023年9月起担任首席财务官、公司秘书。此前，Cross先生自2019年2月起担任生物技术公司Atreca, Inc.的首席财务官。2017年11月至2018年6月，担任生物技术公司ARMO Biosciences，Inc.的首席财务官。2016年2月至2017年11月，Cross先生在生物技术公司Balance Therapeutics，Inc.担任首席财务官。2013年10月至2015年11月，担任生物技术公司KaloBios制药，Inc.的首席财务官，并于2015年1月至2015年11月担任临时首席执行官。2015年12月，KaloBios根据《破产法》第11章提交了一份自愿救济申请。KaloBios于2016年7月从第11章出现。2010年11月至2013年6月，Cross先生在生物技术公司Affymax, Inc.担任首席财务官。2022年7月至2023年8月担任Apexigen，Inc.董事，2019年10月至2023年8月担任Apexigen美国公司董事。Cross先生在加州大学伯克利分校获得工商管理学士学位，是一名注册会计师（非在职）。
- Herb Cross had served as the Chief Financial Officer of Atreca, Inc., a biotechnology company, since February 2019. From November 2017 to June 2018, he served as Chief Financial Officer of ARMO Biosciences, Inc., a biotechnology company. From February 2016 to November 2017, Mr. Cross served as Chief Financial Officer of Balance Therapeutics, Inc., a biotechnology company. From October 2013 to November 2015, he served as Chief Financial Officer of KaloBios Pharmaceuticals, Inc., a biotechnology company, and interim Chief Executive Officer from January 2015 to November 2015. From November 2010 to June 2013, Mr. Cross served as Chief Financial Officer of Affymax, Inc., a biotechnology company. He served as a director of Apexigen, Inc. from July 2022 to August 2023 and Apexigen America, Inc. from October 2019 to August 2023. Mr. Cross received a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive).